IngentaConnect Comparison of rabeprazole 20mg vs. omeprazole 20mg in the treatme...

Authors: Dekkers¹; Beker²; Thjodleifsson³; Gabryelewicz⁴; Bell⁵; Humphries⁵

Source: Alimentary Pharmacology & Therapeutics, Volume 12, Number 8, August 1998 , pp. 789-795(7)

Abstract:

Background:

Rabeprazole sodium is the newest member of a class of substituted benzimidazole molecules known as proton pump inhibitors. Other proton pump inhibitors have been shown to be effective in healing active, benign gastric ulcers. Methods:

In this randomized, double-blind, multicentre study, conducted at 25 European sites, rabeprazole and omeprazole were compared in patients with active gastric ulcers. Two hundred and twenty-seven patients with active benign gastric ulcer were randomized to receive either rabeprazole 20 mg (n = 113) or omeprazole 20 mg (n = 114) once daily for 3 or 6 weeks, with healing monitored by endoscopy. Results:

After 3 weeks, complete healing (ITT analysis) was documented in 58% of patients given rabeprazole and 61% in patients given omeprazole (N.S.). After 6 weeks the healing rates were identical in both groups at 91%. Rabeprazole-treated patients had numerically greater symptom relief at all 12 points of comparison. The differences significantly favoured rabeprazole at week 3 for daytime pain improvement (P = 0.023) and at week 6 for pain frequency (P = 0.006) and complete resolution of night pain (P = 0.022). Both drugs were well-tolerated over the 6-week treatment course. Mean changes from baseline to end-point in fasting serum gastrin were comparable. No significant differences in laboratory parameters were seen. Conclusion:

In this study, rabeprazole produced healing rates comparable to omeprazole at weeks 3 and 6, but provided more consistent and occasionally significantly superior symptom improvement. Both treatments were well-tolerated.

Document Type: Original article

DOI: 10.1046/j.1365-2036.1998.00373.x

Affiliations: 1: Ignatius Hospital, Breda, the Netherlands, 2: St. Antoniushove Hospital, Leidschendam, the Netherlands, 3: The National Hospital of Iceland, Reykjavik, Iceland, 4: Medical Academy of Bialystok, Poland, 5: Eisai Ltd, London, UK

You have access to the full text article on a website external to Ingentaconnect.

Please click here to view this article on InterScience.

You may be required to register and activate access on InterScience before you can obtain the full text. If you have any queries please contact onlinehelp@oxon.blackwellpublishing.com

Comparison of rabeprazole 20 mg vs. omeprazole 20 mg in the treatment of active gastric ulcer—a European multicentre study